Information Provided By: 
Fly News Breaks for November 17, 2019
EIDX
Nov 17, 2019 | 20:37 EDT
Piper Jaffray analyst Tyler Van Buren maintained an Overweight rating and $55 price target on Eidos Therapeutics following "positive" data from the ongoing Phase II OLE presented at the American Heart Association, or AHA, which suggests that "AG10 may be providing patients with superior long-term outcomes relative to Vyndaqel/tafamidis." Van Buren believes these results suggest that AG10 could be "the best-in-class TTR stabilizer" and the analyst now has a "higher level of confidence in the probability of success of the ongoing Phase III trial."
News For EIDX From the Last 2 Days
There are no results for your query EIDX
